Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr 6;6(4):e18210.
doi: 10.1371/journal.pone.0018210.

Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry

Lisa Cosgrove  1 , Ling Shi, David E Creasey, Maria Anaya-McKivergan, Jessica A Myers, Krista F Huybrechts
Affiliations
Review

Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry

Lisa Cosgrove et al. PLoS One. .

Abstract

Background: Antidepressant (AD) use has been purported to increase the risk of breast and ovarian cancer, although both epidemiological and pre-clinical studies have reported mixed results. Previous studies in a variety of biomedical fields have found that financial ties to drug companies are associated with favorable study conclusions.

Methods and findings: We searched English-language articles in MEDLINE, PsychINFO, the Science Citations Index and the Cochrane Central Register of Controlled Clinical Trials (through November 2010). A total of 61 articles that assessed the relationship between breast and ovarian cancer and AD use and articles that examined the effect of ADs on cell growth were included. Multi-modal screening techniques were used to investigate researchers' financial ties with industry. A random effects meta-analysis was used to pool the findings from the epidemiological literature. Thirty-three percent (20/61) of the studies reported a positive association between ADs and cancer. Sixty-seven percent (41/61) of the studies reported no association or antiproliferative effect. The pooled odds ratio for the association between AD use and breast/ovarian cancer in the epidemiologic studies was 1.11 (95% CI, 1.03-1.20). Researchers with industry affiliations were significantly less likely than researchers without those ties to conclude that ADs increase the risk of breast or ovarian cancer. (0/15 [0%] vs 20/46 [43.5%] (Fisher's Exact test P = 0.0012).

Conclusions: Both the pre-clinical and clinical data are mixed in terms of showing an association between AD use and breast and ovarian cancer. The possibility that ADs may exhibit a bi-phasic effect, whereby short-term use and/or low dose antidepressants may increase the risk of breast and ovarian cancer, warrants further investigation. Industry affiliations were significantly associated with negative conclusions regarding cancer risk. The findings have implications in light of the 2009 USPSTF guidelines for breast cancer screening and for the informed consent process.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Literature search and study selection.
Figure 2
Figure 2. Summary of results.
Figure 3
Figure 3. Funnel plot evaluating the presence of publication bias.
Figure 4
Figure 4. Empirical Bayes estimates of the study specific and the pooled estimate for SSRIs.
Figure 5
Figure 5. Empirical Bayes estimates of the study specific and the pooled estimate for TCAs.
See this image and copyright information in PMC

Comment in

References

    1. Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication and breast cancer risk. Am J Epidemiol. 2000;151:951–957. - PubMed
    1. Kelly JP, Rosenberg L, Rao RS, Palmer JR, Shapiro S. Is use of antidepressants associated with the occurrence of breast cancer? Am J Epidemiol. 1998;147(Suppl):S69.
    1. Steingart AB, Cotterchio M. Do antidepressants cause, promote, or inhibit cancers? J Clin Epidemiol. 1995;48(11):1407–1412. - PubMed
    1. Harlow BL, Cramer DW. Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case-control studies. Cancer Causes Control. 1995;6(2):130–134. - PubMed
    1. Brandes LJ, Arron RJ, Bogdanovic RP, Tong J, Zaborniak CLF, et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 1992;52:3796–3800. - PubMed

Substances